Bottom line
RSPH vs FTXH: the short answer
RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) are quite different portfolios: only about 23% of their top holdings (by weight) are shared.
RSPH is cheaper at 0.4% vs 0.6% — a difference of $20 a year per $10,000 invested.
Over five years, FTXH returned +6.5% a year vs +4.7% for RSPH.
Updated Nov 19, 2026
RSPH vs FTXH side by side
| RSPH | FTXH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.4% | 0.6% |
| Annual cost per $10k | $40 | $60 |
| 10-yr cost on $10k (prospectus) | $505 | — |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +9.3% | +24.0% |
| 5-yr return (annualized) | +4.7% | +6.5% |
| 10-yr return (annualized) | +8.2% | — |
| Best quarter | +17.5% | +18.3% |
| Worst quarter | −14.3% | −17.4% |
| Net assets (fund) | $766.9M | $36.2M |
| Number of holdings | 63 | 51 |
| Portfolio turnover | 24% | 35% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RSPH | FTXH | Difference |
|---|---|---|---|
| 2025 | +9.3% | +24.0% | −14.7% |
| 2024 | −0.8% | +3.0% | −3.8% |
| 2023 | +3.9% | −1.4% | +5.4% |
| 2022 | −9.2% | +2.5% | −11.8% |
| 2021 | +23.0% | +6.1% | +16.9% |
| 2020 | +18.9% | +10.9% | +8.0% |
| 2019 | +25.3% | +22.4% | +3.0% |
| 2018 | −0.3% | −8.4% | +8.0% |
| 2017 | +23.4% | +18.8% | +4.6% |
Source: Fund prospectus bar charts
Holdings overlap
7 of RSPH's top 25 holdings also appear in FTXH's top 25.
| Holding | RSPH | FTXH |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 1.96% | 2.72% |
| Charles River Laboratories International, Inc. | 1.93% | 1.49% |
| Bristol-Myers Squibb Co. | 1.82% | 6.29% |
| Amgen Inc. | 1.77% | 3.18% |
| Incyte Corp. | 1.76% | 2.39% |
| AbbVie Inc. | 1.73% | 7.39% |
| Viatris Inc. | 1.72% | 3.62% |
Source: SEC Form N-PORT
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between RSPH and FTXH?
Which is cheaper, RSPH or FTXH?
Should I own both RSPH and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.